Literature DB >> 27320797

Hepatic cytochromes P450: structural degrons and barcodes, posttranslational modifications and cellular adapters in the ERAD-endgame.

Sung-Mi Kim1, YongQiang Wang1, Noushin Nabavi1, Yi Liu1, Maria Almira Correia1,2,3,4.   

Abstract

The endoplasmic reticulum (ER)-anchored hepatic cytochromes P450 (P450s) are enzymes that metabolize endo- and xenobiotics i.e. drugs, carcinogens, toxins, natural and chemical products. These agents modulate liver P450 content through increased synthesis or reduction via inactivation and/or proteolytic degradation, resulting in clinically significant drug-drug interactions. P450 proteolytic degradation occurs via ER-associated degradation (ERAD) involving either of two distinct routes: Ubiquitin (Ub)-dependent 26S proteasomal degradation (ERAD/UPD) or autophagic lysosomal degradation (ERAD/ALD). CYP3A4, the major human liver/intestinal P450, and the fast-turnover CYP2E1 species are degraded via ERAD/UPD entailing multisite protein phosphorylation and subsequent ubiquitination by gp78 and CHIP E3 Ub-ligases. We are gaining insight into the nature of the structural determinants involved in CYP3A4 and CYP2E1 molecular recognition in ERAD/UPD [i.e. K48-linked polyUb chains and linear and/or "conformational" phosphodegrons consisting either of consecutive sequences on surface loops and/or disordered regions, or structurally-assembled surface clusters of negatively charged acidic (Asp/Glu) and phosphorylated (Ser/Thr) residues, within or vicinal to which, Lys-residues are targeted for ubiquitination]. Structural inspection of select human liver P450s reveals that such linear or conformational phosphodegrons may indeed be a common P450-ERAD/UPD feature. By contrast, although many P450s such as the slow-turnover CYP2E1 species and rat liver CYP2B1 and CYP2C11 are degraded via ERAD/ALD, little is known about the mechanism of their ALD-targeting. On the basis of our current knowledge of ALD-substrate targeting, we propose a tripartite conjunction of K63-linked Ub-chains, P450 structural "LIR" motifs and selective cellular "cargo receptors" as plausible P450-ALD determinants.

Entities:  

Keywords:  26S proteasome; CHIP; Cytochromes P450; E2/E3 ubiquitin ligases; ERAD; K48 & K63 ubiquitination; autophagic lysosomal degradation; gp78 E3; p62; p97; phosphodegrons

Mesh:

Substances:

Year:  2016        PMID: 27320797      PMCID: PMC5094896          DOI: 10.1080/03602532.2016.1195403

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  220 in total

Review 1.  p97 and close encounters of every kind: a brief review.

Authors:  I Dreveny; V E Pye; F Beuron; L C Briggs; R L Isaacson; S J Matthews; C McKeown; X Yuan; X Zhang; P S Freemont
Journal:  Biochem Soc Trans       Date:  2004-11       Impact factor: 5.407

2.  Cell biology. Autophagy's top chef.

Authors:  Ana Maria Cuervo
Journal:  Science       Date:  2011-06-17       Impact factor: 47.728

3.  Pharmacokinetic consequences of induction of CYP2E1 by ligand stabilization.

Authors:  J Y Chien; K E Thummel; J T Slattery
Journal:  Drug Metab Dispos       Date:  1997-10       Impact factor: 3.922

4.  Ligand-dependent maintenance of ethanol-inducible cytochrome P-450 in primary rat hepatocyte cell cultures.

Authors:  E Eliasson; I Johansson; M Ingelman-Sundberg
Journal:  Biochem Biophys Res Commun       Date:  1988-01-15       Impact factor: 3.575

5.  The tumor autocrine motility factor receptor, gp78, is a ubiquitin protein ligase implicated in degradation from the endoplasmic reticulum.

Authors:  S Fang; M Ferrone; C Yang; J P Jensen; S Tiwari; A M Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-27       Impact factor: 11.205

6.  Human liver cytochrome P450 3A4 ubiquitination: molecular recognition by UBC7-gp78 autocrine motility factor receptor and UbcH5a-CHIP-Hsc70-Hsp40 E2-E3 ubiquitin ligase complexes.

Authors:  YongQiang Wang; Sung-Mi Kim; Michael J Trnka; Yi Liu; A L Burlingame; Maria Almira Correia
Journal:  J Biol Chem       Date:  2014-12-01       Impact factor: 5.157

7.  Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling.

Authors:  Jörn M Schattenberg; Yongjun Wang; Rajat Singh; Raina M Rigoli; Mark J Czaja
Journal:  J Biol Chem       Date:  2005-01-04       Impact factor: 5.157

8.  Global analysis of lysine ubiquitination by ubiquitin remnant immunoaffinity profiling.

Authors:  Guoqiang Xu; Jeremy S Paige; Samie R Jaffrey
Journal:  Nat Biotechnol       Date:  2010-07-18       Impact factor: 54.908

9.  A role for protein phosphorylation in cytochrome P450 3A4 ubiquitin-dependent proteasomal degradation.

Authors:  Yongqiang Wang; Mingxiang Liao; Nicholas Hoe; Poulomi Acharya; Changhui Deng; Andrew N Krutchinsky; Maria Almira Correia
Journal:  J Biol Chem       Date:  2008-12-18       Impact factor: 5.157

Review 10.  Recognition and processing of ubiquitin-protein conjugates by the proteasome.

Authors:  Daniel Finley
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

View more
  11 in total

1.  Post-transcriptional Regulation of UGT2B10 Hepatic Expression and Activity by Alternative Splicing.

Authors:  Adrien Labriet; Eric P Allain; Michèle Rouleau; Yannick Audet-Delage; Lyne Villeneuve; Chantal Guillemette
Journal:  Drug Metab Dispos       Date:  2018-02-09       Impact factor: 3.922

2.  Sulfenylation of Human Liver and Kidney Microsomal Cytochromes P450 and Other Drug-Metabolizing Enzymes as a Response to Redox Alteration.

Authors:  Matthew E Albertolle; Thanh T N Phan; Ambra Pozzi; F Peter Guengerich
Journal:  Mol Cell Proteomics       Date:  2018-01-26       Impact factor: 5.911

3.  Induction via Functional Protein Stabilization of Hepatic Cytochromes P450 upon gp78/Autocrine Motility Factor Receptor (AMFR) Ubiquitin E3-Ligase Genetic Ablation in Mice: Therapeutic and Toxicological Relevance.

Authors:  Doyoung Kwon; Sung-Mi Kim; Peyton Jacob; Yi Liu; Maria Almira Correia
Journal:  Mol Pharmacol       Date:  2019-09-06       Impact factor: 4.436

Review 4.  Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions.

Authors:  Jaydeep Yadav; Erickson Paragas; Ken Korzekwa; Swati Nagar
Journal:  Pharmacol Ther       Date:  2019-12-11       Impact factor: 12.310

5.  miRNA-122 Protects Mice and Human Hepatocytes from Acetaminophen Toxicity by Regulating Cytochrome P450 Family 1 Subfamily A Member 2 and Family 2 Subfamily E Member 1 Expression.

Authors:  Vivek Chowdhary; Kun-Yu Teng; Sharda Thakral; Bo Zhang; Cho-Hao Lin; Nissar Wani; Lei Bruschweiler-Li; Xiaoli Zhang; Laura James; Dakai Yang; Norman Junge; Rafael Brüschweiler; William M Lee; Kalpana Ghoshal
Journal:  Am J Pathol       Date:  2017-09-28       Impact factor: 4.307

6.  Characterization of the structural determinants of the ubiquitin-dependent proteasomal degradation of human hepatic tryptophan 2,3-dioxygenase.

Authors:  Yi Liu; Sung-Mi Kim; YongQiang Wang; Shay Karkashon; Ariel Lewis-Ballester; Syun-Ru Yeh; Maria Almira Correia
Journal:  Biochem J       Date:  2021-05-28       Impact factor: 3.857

7.  Why Hepatic CYP2E1-Elevation by Itself Is Insufficient for Inciting NAFLD/NASH: Inferences from Two Genetic Knockout Mouse Models.

Authors:  Maria Almira Correia; Doyoung Kwon
Journal:  Biology (Basel)       Date:  2020-11-26

8.  Induction by Phenobarbital of Phase I and II Xenobiotic-Metabolizing Enzymes in Bovine Liver: An Overall Catalytic and Immunochemical Characterization.

Authors:  Michela Cantiello; Monica Carletti; Mery Giantin; Giulia Gardini; Francesca Capolongo; Paolo Cascio; Marianna Pauletto; Flavia Girolami; Mauro Dacasto; Carlo Nebbia
Journal:  Int J Mol Sci       Date:  2022-03-24       Impact factor: 5.923

Review 9.  MicroRNAs and cancer drug resistance: over two thousand characters in search of a role.

Authors:  Bruno Costa Gomes; José Rueff; António Sebastião Rodrigues
Journal:  Cancer Drug Resist       Date:  2019-09-19

10.  The cholesterol synthesis enzyme lanosterol 14α-demethylase is post-translationally regulated by the E3 ubiquitin ligase MARCH6.

Authors:  Nicola A Scott; Laura J Sharpe; Isabelle M Capell-Hattam; Samuel J Gullo; Winnie Luu; Andrew J Brown
Journal:  Biochem J       Date:  2020-01-31       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.